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passing rate for target volumes was found to be above 96% 
for a 3%/3mm criteria. Differences in tumor control 
probability were within 2.5% for liver and breast, however, 
for head-and-neck and prostate patients the differences were 
up to 6.5% and up to 11% for lung patients. 
We conclude that approximations introduced in analytical 
dose calculation methods can result in significant range 
uncertainties for heterogeneous patient geometries or 
introduce a systematically reduced dose in target volumes. 
Routine MC simulations for treatment planning or verification 
may be necessary to ensure full target coverage to the 
prescribed dose levels.  In particular for clinical trials 
comparing photon vs. proton treatments, MC simulations may 
be required to avoid bias due to differences in dose 
calculations. 
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This talk describes the reference dosimetry of clinical proton 
beams. The main goal is to clarify the application of the IAEA 
TRS-398 dosimetry Code of Practice to modern proton beam 
delivery systems. A clear distinction is made between (i) 
those proton beam delivery systems that should be calibrated 
with an SOBP field, and (ii) those delivery systems that 
should be calibrated with a mono-energetic field. For these 
second type of delivery systems, a word of caution is issued 
on the use of cylindrical ionisation chambers. Contrary to the 
IAEA TRS-398 recommendations, this talk presents different 
arguments in favour of taking the effective point of 
measurement of cylindrical chambers into account when 
positioning the reference point of the chamber at the 
measurement depth. Finally, this talk also discusses the 
comparison between reference dosimetry and other 
independent dosimetry techniques, such as Faraday cup 
dosimetry and water calorimetry. 
   
SP-0113  
Myth and reality of image guidance and adaptive 
treatments in proton therapy 
M. Engelsman1 
1Delft University of Technology, Holland PTC, Delft, The 
Netherlands   
  
The finite range of protons makes the delivered dose 
distribution, particularly in case of IMPT, very sensitive to 
any uncertainty and change in patient anatomy. In the best 
case, the patient anatomy and the treatment plans are 
robust over the entire treatment course such that treatment 
adaptation is not necessary. Adaptive therapy is, however, 
not simply a buzz-word, especially not for the relatively new 
indications for proton therapy in the thoracic and pelvic 
region. Existing and new proton therapy centers are working 
towards a framework that allows them to 
1) determine which patients will benefit from a treatment 
adaptation. 
2) efficiently adapt and validate the treatment plan. 
The tools for such a framework are; volumetric image-
guidance, dose-recalculation and accumulation, and plan-
reoptimization. This presentation will discuss the needs for 
these tools, their availability and integration, and the current 
reality in plan adaptation in proton therapy. 
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The benefit of intensity-modulated radiation therapy (IMRT) 
in the treatment of head-and-neck cancer (HNC) has been 
demonstrated in numerous studies. Highly conformal 
radiation allows for a high dose to high-risk areas, whilst 
sparing adjacent organs at risk (OAR) such as the parotid 
glands. Clinical studies have shown that IMRT reduces grade-3 
xerostomia in comparison to three-dimensional conformal 
radiotherapy. The next step is to develop dose-escalation 
studies, that so called “Dose painting”. Dose-painting IMRT is 
aimed at exploiting inhomogeneous dose distributions 
adapted to tumor heterogeneity. Tumor regions of increased 
radiation resistance receive escalated dose levels, whereas 
radiation-sensitive regions receive conventional or even de-
escalated dose levels. Dose painting relies on biologic 
imaging. On the other hand, the changes to the dose 
distribution during treatment based on specific  patients 
variations due to weight loss and tumor shrink must be 
corrected. For that purpose Adaptative Radiotherapy is 
developed. This is done by means of:  
a)  Image guided RT: Repositioning of the patient at the time 
of treatment  
b)  Dose tracking: Computiong fraction dose based on daily 
cone-beam CT, accumulating dose by deformable registration 
and evaluating the accumulated dose at different organs 
c)  Replanning: Adapt the dose to a systematic volumentric 
changes and compensate for undesired dose accumulation. 
We will review the whole process and we will discuss the 
clinical data published and some of the new trials that are 
under evaluation. 
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Radiotherapy is an integral part of soft tissue sarcoma (STS) 
multidisciplinary management, with local control in excess of 
90 % for disease arising in the extremities. 
From our recently published Phase 2 study of preoperative 
image-guided intensity modulated radiation therapy (IG-
IMRT) to reduce wound and combined modality morbidities 
in lower extremity soft tissue sarcoma (LE-STS), 
approximately 20 % of the patient population required 
replanning during their course of radiation therapy (RT) due 
to soft tissue/tumour volume changes exceeding 1 cm as 
measured on daily cone beam CT localization used for RT 
guidance.   
Previous work evaluated the dosimetric effect of tumour 
volume changes (TVC) for preoperative IMRT of LE-STS to 
determine critical indicators, as measured on daily CBCT 
localization, to motivate plan adaptation.  We found that a 1 
cm TVC deviation on CBCT imaging was a reliable threshold 
